Examination of transdermal berberine delivery, GLP-1 pathway terminology in supplement marketing, and consumer evaluation ...

Lately, those of us who want help losing weight have more options than ever before. So what exactly is the best weight loss ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including ...

Tirzepatide can cost $500 to $1,900 a month without insurance. More affordable tirzepatide alternatives include semaglutide, ...

According to the Gallup Health and Well-Being Index from October 2025, the U.S. adult obesity rate declined to 37%, down from a record high of 39.9% in 2022. 12.4% of U.S. adults now report taking GLP ...

Regulators at the U.S. Food and Drug Administration on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The ...

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration's ...

The US Food and Drug Administration today approved a pill version of the blockbuster anti-obesity drug Wegovy. Made by Novo Nordisk, the pill is taken once a day. The company’s original version of ...

As the end of 2025 approaches, Human Resources reminds employees of important deadlines, dates and information. HR also shares what to expect in 2026, including AmeriBen serving as the new ...